Immuneering Corporation (IMRX)
$3.56-7.77%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $129M
- Beta
- 0.39
- P/E (TTM)
- -3.42
- Short % float
- 61.41%
- Days to cover
- 24.2
- SI change
- -0.4%
- 1W
- -7.05%
- 1M
- -17.78%
- vs SPY 1W
- -7.47%
- vs SPY 1M
- -19.84%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IMRX?
- LOPJLB’s latest quantitative signal on Immuneering Corporation (IMRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMRX in?
- Immuneering Corporation (IMRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immuneering Corporation (IMRX) do?
- Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specificall…